European Journal of Cardio-Thoracic Surgery, Vol 8, 511-516, Copyright © 1994 by European Association for Cardio-thoracic Surgery
Evaluating intraoperative radiation therapy (IORT) and external beam radiation therapy (EBRT) in non-small cell lung cancer (NSCLC). Five years experience
FM Smolle-Juettner, E Geyer, KS Kapp, B Ratzenhofer, G Stuecklschweiger, NB Kaufmann, J Smolle, GM Pongratz, A Hackl and G Friehs
Department Thoracic and Hyperbaric Surgery, University Medical School, Graz, Austria.
A pilot study on intraoperative radiation therapy (IORT) combined with
external beam radiation therapy (EBRT) in nonresectable non-small cell lung
cancer (NSCLC) was performed in 31 patients (mean age: 66.2 years, range:
51-80; 10 anatomically and functionally, 21 functionally, nonresectable; 20
squamous-cell, 11 adenocarcinoma). The tumor was exposed by lateral
thoracotomy and a staging lymph node dissection was performed (final
staging 7 T1, 16 T2, 8 T3; 11 nodal positive). Ten to 20 Gy IORT (energy:
7-20 MeV electrons) were delivered to the tumor. Unilateral continuous
positive airway pressure ventilation of the diseased lung was used to
reduce the amount of healthy lung tissue in the IORT port and to minimize
the ventilatory movement. Secondary collimation and direct shielding of
radio-sensitive structures within the IORT port by aluminium sheets were
used to further reduce collateral damage. Four weeks after IORT, 46 Gy EBRT
(2 Gy/day 5 times a week; 8-23 MeV photons) were administered to the
mediastinum and to the tumor-bearing area on an outpatient basis. In nodal
positive cases the mediastinal dose was increased to 56 Gy. Twenty-three
patients were evaluable. In 13 complete, in 8 partial (50-97% regression)
and in 2 minor response has been achieved. Five patients experienced a
recurrence (local only: 2; local and distant: 1; distant only: 2). Twelve
patients died of underlying cardio-respiratory disorders within 6 to 25
months after IORT; 7 died of cancer. The overall 5-year survival rate
including the incidental deaths is 14.7%. The recurrence- free survival
rate is 53.2%.